Adage Capital Partners Gp, L.L.C. Intellia Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$34.58 - $46.03 $103,740 - $138,090	-3,000 Reduced 4.76%	60,000 $2.45 Million
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $6.66 Million - $8.96 Million	-200,000 Reduced 76.05%	63,000 $2.35 Million
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $2.06 Million - $3.89 Million	-62,000 Reduced 19.08%	263,000 $9.18 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $8.04 Million - $10.7 Million	149,022 Added 84.68%	325,000 $18.2 Million
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $192,450 - $381,049	5,000 Added 2.92%	175,978 $9.11 Million
Q1 2022 May 16, 2022	SELL	$58.27 - $118.99 $31.8 Million - $65 Million	-546,500 Reduced 76.17%	170,978 $12.4 Million
Q3 2021 Nov 15, 2021	BUY	$132.37 - $176.78 $33.7 Million - $45 Million	254,500 Added 54.97%	717,478 $96.3 Million
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $28.2 Million - $75 Million	462,978 New	462,978 $75 Million

317

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $835M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.